Wednesday, February 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Is it a Bacterial or Viral Infection? Novel MeMed Rapid Test Receives FDA Clearance

by Global Biodefense Staff
September 24, 2021
Is it a Bacterial or Viral Infection? Novel MeMed Rapid Test Receives FDA Clearance

The MeMed Key diagnostic tool recently received full FDA licensure. Courtesy photo: Defense Threat Reduction Agency's Chemical and Biological Technologies Department

Novel host response protein signature technology can rapidly distinguish between bacterial and viral infections to speed treatment decisions and combat the growing threat of Antimicrobial Resistance.

The MeMed Key diagnostic tool recently received full FDA licensure after four years of research, development, and investments by Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department in its role as the Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense Program.

Each year in the United States, about three million Americans fall ill to antibiotic-resistant infections, and 35,000 die from those illnesses. To definitively answer whether an infection is bacterial versus viral, DTRA-JSTO has been investing in the MeMed Key program efforts.

Utilizing MeMed Key, patients will be able to visit their local health clinics and – in as little as 15 minutes with blood from a finger prick – be able to identify whether their symptoms are due to an active bacterial or viral infection.

MeMed Key is a first of its kind immunoassay platform, that opens the way to measuring multiple proteins with central lab performance at the point-of-need.

“This new technology will better position us to identify emerging threats and reduce the use of unnecessary medical countermeasures such as antibiotics,” said Richard Schoske, Ph.D., chief for DTRA-JSTO’s Diagnostics and Detection efforts.

DTRA-JSTO invested $9.2 million in 2017 to fund the completion of MeMed’s pioneering point of care platform for distinguishing bacterial from viral infections. In 2018, the DOD’s Congressionally Directed Medical Research Programs (CDMRP) awarded the company an additional $4.1 million to support transition of the company’s prototype ImmunoPoC point-of-care (POC) blood-testing platform toward a final product, including transfer to manufacturing and implementation of cloud connectivity.

Tags: AntimicrobialsEditor PickPOC Diagnostics

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States
Industry News

Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States

September 7, 2022
Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response
Industry News

Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response

August 31, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC